

(12) PATENT APPLICATION
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 200068075 A1

(54) Title
Novel nucleotide sequences coding for the poxB gene

(51)⁷ International Patent Classification(s)
C12N 015/52 C12P 013/08
C12N 015/63

(21) Application No: 200068075

(22) Application Date: 2000.10.25

(30) Priority Data

(31) Number	(32) Date	(33) Country
199519757	1999.10.28	DE

(43) Publication Date : 2001.05.03

(43) Publication Journal Date : 2001.05.03

(71) Applicant(s)
Degussa-Huls Aktiengesellschaft

(72) Inventor(s)
Nicole Dusch; Walter Pfefferle; Anke Weissenborn; Bettina Mockel; Alfred Puhler; Jorn Kalinowski; Brigitte Bathe

(74) Agent/Attorney
SPRUSON and FERGUSON, GPO Box 3898, SYDNEY NSW 2001

Novel Nucleotide Sequences Coding for the poxB Gene

Abstract

An isolated polynucleotide containing a polynucleotide sequence selected from the group

- a) polynucleotide which is at least 70% identical to a polynucleotide which codes for a polypeptide containing the amino acid sequence of SEQ ID no. 2,
 - b) polynucleotide which codes for a polypeptide which contains an amino acid sequence which is at least 70% identical to the amino acid sequence of SEQ ID no. 2,
 - c) polynucleotide which is complementary to the polynucleotides of a) or b), and
 - d) polynucleotide containing at least 15 successive bases of the polynucleotide sequence of a), b) or c),
- and a process for the fermentative production of L-amino acids by attenuation of the poxB gene.

AUSTRALIA

PATENTS ACT 1990

COMPLETE SPECIFICATION

FOR A STANDARD PATENT

ORIGINAL

Name and
Address
of Applicant :

Degussa-Huls Aktiengesellschaft
DE-60287 Frankfurt am Main
Germany

Actual
Inventor(s):

Nicole Dusch, Brigitte Bathe, Jorn Kalinowski, Alfred
Puhler, Bettina Mockel, Anke Weissenborn and Walter
Pfefferle

Address for
Service:

Spruson & Ferguson
St Martins Tower
31 Market Street
Sydney NSW 2000

Invention Title:

Novel Nucleotide Sequences Coding for the poxB Gene

The following statement is a full description of this invention, including the best method of performing it known to me/us:-

Novel nucleotide sequences coding for the poxB gene

The present invention provides nucleotide sequences from coryneform bacteria coding for the poxB gene and a process for the fermentative production of amino acids, in particular L-lysine, by attenuation of the poxB gene.

Prior art

L-amino acids, in particular lysine, are used in human medicine and in the pharmaceuticals industry, in the food industry and very particularly in animal nutrition.

- 10 It is known that amino acids are produced by fermentation of strains of coryneform bacteria, in particular *Corynebacterium glutamicum*. Due to their great significance, efforts are constantly being made to improve the production process. Improvements to the process may
- 15 relate to measures concerning fermentation technology, for example stirring and oxygen supply, or to the composition of the nutrient media, such as for example sugar concentration during fermentation, or to working up of the product by, for example, ion exchange chromatography, or to
- 20 the intrinsic performance characteristics of the microorganism itself.

- The performance characteristics of these microorganisms are improved using methods of mutagenesis, selection and mutant selection. In this manner, strains are obtained which are
- 25 resistant to antimetabolites or are auxotrophic for regulatorily significant metabolites and produce amino acids.

- For some years, methods of recombinant DNA technology have also been used to improve strains of *Corynebacterium* which
- 30 produce L-amino acids.

Object of the invention

The inventors set themselves the object of providing novel measures for the improved fermentative production of amino acids, in particular L-lysine.

990159 BT / AL

Description of the Invention

L-amino acids, in particular lysine, are used in human medicine and in the pharmaceuticals industry, in the food industry and very particularly in animal nutrition. There is accordingly general interest in providing novel improved processes for the production of amino acids, in particular

5 L-lysine.

The present invention provides an isolated polynucleotide containing a polynucleotide sequence selected from the group

- a) polynucleotide which is at least 70% identical to a polynucleotide which codes for a polypeptide containing the amino acid sequence of SEQ ID no. 2,
- 10 b) polynucleotide which codes for a polypeptide which contains an amino acid sequence which is at least 70% identical to the amino acid sequence of SEQ ID no. 2,
- c) polynucleotide which is complementary to the polynucleotides of a) or b), and
- d) polynucleotide containing at least 15 successive bases of the polynucleotide sequence of a), b) or c).
- 15 The present invention also provides the polynucleotide wherein it preferably comprises replicable DNA containing:
 - (i) the nucleotide sequence shown in SEQ ID no. 1, or
 - (ii) at least one sequence which matches the sequence (i) within the degeneration range of the genetic code, or
 - 20 (iii) at least one sequence which hybridises with the complementary sequence to sequence (i) or (ii) and optionally

(iv) functionally neutral sense mutations in (i).

The present invention also provides

a polynucleotide containing the nucleotide sequence as shown in SEQ ID no. 1,

5 a polynucleotide which codes for a polypeptide which contains the amino acid sequence as shown in SEQ ID no. 2,

a vector containing the polynucleotide of the invention in particular pCR2.1poxBint, deposited in *E. coli* DSM 13114.

and coryneform bacteria acting as host cell which contain an insertion or deletion of the pox gene.

10 The present invention also provides polynucleotides which substantially consist of a polynucleotide sequence, which are obtainable by screening by means of hybridisation of a suitable gene library, which contains the complete gene having the polynucleotide sequence according to SEQ ID no. 1, with a probe which contains the sequence of the stated polynucleotide according to SEQ ID no. 1, or a fragment thereof, and isolation of the stated DNA sequence.

15 Polynucleotide sequences according to the invention are suitable as hybridisation probes for RNA, cDNA and DNA in order to isolate full length cDNA which code for pyruvate oxidase and to isolate such cDNA or genes, the sequence of which exhibits a high level of similarity with that of the pyruvate oxidase gene.

20 Polynucleotide sequences according to the invention are furthermore suitable as primers for the production of DNA of genes which code for pyruvate oxidase by the polymerase chain reaction (PCR).

Such oligonucleotides acting as probes or primers contain at least 30, preferably at least 20, very particularly preferably at least 15 successive nucleotides.

Oligonucleotides having a length of at least 40 or 50 bases
5 are also suitable.

"Isolated" means separated from its natural environment.

"Polynucleotide" generally relates to polyribonucleotides and polydeoxyribonucleotides, wherein the RNA or DNA may be unmodified or modified.

10 "Polypeptides" are taken to mean peptides or proteins which contain two or more amino acids connected by peptide bonds.

The polypeptides according to the invention include a polypeptide according to SEQ ID no. 2, in particular those having the biological activity of pyruvate oxidase and also

15 those which are at least 70%, preferably at least 80% and in particular 90% to 95% identical to the polypeptide according to SEQ ID no. 2 and exhibit the stated activity.

The invention furthermore relates to a process for the fermentative production of amino acids, in particular

20 lysine, using coryneform bacteria, which in particular already produce the amino acids, in particular L-lysine, and in which the nucleotide sequences which code for the poxB gene are attenuated, in particular are expressed at a low level.

25 In this connection, the term "attenuation" means reducing or suppressing the intracellular activity of one or more enzymes (proteins) in a microorganism, which enzymes are coded by the corresponding DNA, for example by using a weak promoter or a gene or allele which codes for a

30 corresponding enzyme which has a low activity or inactivates the corresponding gene or enzyme (protein) and optionally by combining these measures.

- The microorganisms, provided by the present invention, may produce amino acids, in particular lysine, from glucose, sucrose, lactose, fructose, maltose, molasses, starch, cellulose or from glycerol and ethanol. The microorganisms
- 5 may comprise representatives of the coryneform bacteria in particular of the genus *Corynebacterium*. Within the genus *Corynebacterium*, the species *Corynebacterium glutamicum* may in particular be mentioned, which is known in specialist circles for its ability to produce L-amino acids.
- 10 Suitable strains of the genus *Corynebacterium*, in particular of the species *Corynebacterium glutamicum*, are the known wild type strains
- Corynebacterium glutamicum* ATCC13032
- Corynebacterium acetoglutamicum* ATCC15806
- 15 *Corynebacterium acetoacidophilum* ATCC13870
- Corynebacterium melassecola* ATCC17965
- Corynebacterium thermoaminogenes* FERM BP-1539
- Brevibacterium flavum* ATCC14067
- Brevibacterium lactofermentum* ATCC13869 and
- 20 *Brevibacterium divaricatum* ATCC14020
- and mutants or strains produced therefrom which produce L-amino acids,
- such as for example the L-lysine producing strains
- Corynebacterium glutamicum* FERM-P 1709 ,
- 25 *Brevibacterium flavum* FERM-P 1708
- Brevibacterium lactofermentum* FERM-P 1712
- Corynebacterium glutamicum* FERM-P 6463
- Corynebacterium glutamicum* FERM-P 6464 and
- Corynebacterium glutamicum* DSM 5714. The
- 30 inventors succeeded in isolating the novel *poxB* gene, which codes for the enzyme pyruvate oxidase (EC 1.2.2.2), from *C. glutamicum*.

The *poxB* gene or also other genes are isolated from *C. glutamicum* by initially constructing a gene library of this

- microorganism in *E. coli*. The construction of gene libraries is described in generally known textbooks and manuals. Examples which may be mentioned are the textbook by Winnacker, *Gene und Klon, Eine Einführung in die Gentechnologie* (Verlag Chemie, Weinheim, Germany, 1990) or the manual by Sambrook et al., *Molecular Cloning, A Laboratory Manual* (Cold Spring Harbor Laboratory Press, 1989). One very well known gene library is that of *E. coli* K-12 strain W3110, which was constructed by Kohara et al. (Cell 50, 495-508 (1987)) in λ vectors. Bathe et al. (Molecular and General Genetics, 252:255-265, 1996) describe a gene library of *C. glutamicum* ATCC13032, which was constructed using the cosmid vector SuperCos I (Wahl et al., 1987, Proceedings of the National Academy of Sciences USA, 84:2160-2164) in *E. coli* K-12 strain NM554 (Raleigh et al., 1988, Nucleic Acids Research 16:1563-1575). Börmann et al. (Molecular Microbiology 6(3), 317-326, 1992) also describe a gene library of *C. glutamicum* ATCC13032, using cosmid pHC79 (Hohn and Collins, Gene 11, 291-298 (1980)). O'Donohue (The Cloning and Molecular Analysis of Four Common Aromatic Amino Acid Biosynthetic Genes from *Corynebacterium glutamicum*. Ph.D. Thesis, National University of Ireland, Galway, 1997) describes the cloning of *C. glutamicum* genes using the λ Zap expression system described by Short et al. (Nucleic Acids Research, 16: 7583).

- A gene library of *C. glutamicum* in *E. coli* may also be produced using plasmids such as pBR322 (Bolivar, Life Sciences, 25, 807-818 (1979)) or pUC9 (Vieira et al., 1982, Gene, 19:259-268). Suitable hosts are in particular those *E. coli* strains with restriction and recombination defects, such as for example strain DH5 α (Jeffrey H. Miller: "A Short Course in Bacterial Genetics, A Laboratory Manual and Handbook for *Escherichia coli* and Related Bacteria", Cold Spring Harbor Laboratory Press, 1992).

The long DNA fragments cloned with the assistance of cosmids or other λ vectors may then in turn be sub-cloned in conventional vectors suitable for DNA sequencing.

DNA sequencing methods are described inter alia in Sanger et al. (Proceedings of the National Academy of Sciences of the United States of America USA, 74:5463-5467, 1977).

The resultant DNA sequences may then be investigated using known algorithms or sequence analysis programs, for example Staden's program (Nucleic Acids Research 14, 217-232(1986)), Butler's GCG program (Methods of Biochemical Analysis 39, 74-97 (1998)), Pearson & Lipman's FASTA algorithm (Proceedings of the National Academy of Sciences USA 85,2444-2448 (1988)) or Altschul et al.'s BLAST algorithm (Nature Genetics 6, 119-129 (1994)) and compared with the sequence entries available in publicly accessible databases. Publicly accessible nucleotide sequence databases are, for example, the European Molecular Biology Laboratory database (EMBL, Heidelberg, Germany) or the National Center for Biotechnology Information database (NCBI, Bethesda, MD, USA).

The novel DNA sequence from *C. glutamicum* which codes for the *poxB* gene and, as SEQ ID no. 1, is provided by the present invention, was obtained in this manner. The amino acid sequence of the corresponding protein was furthermore deduced from the above DNA sequence using the methods described above. SEQ ID no. 2 shows the resultant amino acid sequence of the product of the *poxB* gene.

Coding DNA sequences arising from SEQ ID no. 1 due to the degeneracy of the genetic code are also provided by the present invention. DNA sequences which hybridize with SEQ ID no. 1 or parts of SEQ ID no. 1 are similarly provided by the invention. Finally, DNA sequences produced by the polymerase chain reaction (PCR) using primers obtained from SEQ ID no. 1 are also provided by the present invention.

The person skilled in the art may find instructions for identifying DNA sequences by means of hybridization inter alia in the manual "The DIG System Users Guide for Filter Hybridization" from Boehringer Mannheim GmbH (Mannheim, Germany, 1993) and in Liebl et al. (International Journal of Systematic Bacteriology (1991) 41: 255-260). 255-260). The person skilled in the art may find instructions for amplifying DNA sequences using the polymerase chain reaction (PCR) inter alia in the manual by Gait, 10 Oligonucleotide synthesis: a practical approach (IRL Press, Oxford, UK, 1984) and in Newton & Graham, PCR (Spektrum Akademischer Verlag, Heidelberg, Germany, 1994).

The inventors discovered that coryneform bacteria produce L-amino acids, in particular L-lysine, in an improved 15 manner once the poxB gene has been attenuated.

Attenuation may be achieved by reducing or suppressing either expression of the poxB gene or the catalytic properties of the enzyme protein. Both measures may optionally be combined.

20 Reduced gene expression may be achieved by appropriate control of the culture or by genetic modification (mutation) of the signal structures for gene expression. Signal structures for gene expression are, for example, repressor genes, activator genes, operators, promoters, 25 attenuators, ribosome binding sites, the start codon and terminators. The person skilled in the art will find information in this connection for example in patent application WO 96/15246, in Boyd & Murphy (Journal of Bacteriology 170: 5949 (1988)), in Voskuil & Chambliss 30 (Nucleic Acids Research 26: 3548 (1998)), in Jensen & Hammer (Biotechnology and Bioengineering 58: 191 (1998)), in Patek et al. (Microbiology 142: 1297 (1996)) and in known textbooks of genetics and molecular biology, such as for example the textbook by Knippers ("Molekulare Genetik", 35 6th edition, Georg Thieme Verlag, Stuttgart, Germany, 1995)

or by Winnacker ("Gene und Klone", VCH Verlagsgesellschaft, Weinheim, Germany, 1990).

- Mutations which give rise to a change or reduction in the catalytic properties of enzyme proteins are known from the prior art; examples which may be mentioned are the papers by Qiu and Goodman (Journal of Biological Chemistry 272: 8611-8617 (1997)), Sugimoto et al. (Bioscience Biotechnology and Biochemistry 61: 1760-1762 (1997)) and Möckel ("Die Threonindehydratase aus Corynebacterium glutamicum: Aufhebung der allosterischen Regulation und Struktur des Enzyms", Berichte des Forschungszentrums Jülichs, Jül-2906, ISSN09442952, Jülich, Germany, 1994). Summary presentations may be found in known textbooks of genetics and molecular biology such as, for example, the textbook by Hagemann ("Allgemeine Genetik", Gustav Fischer Verlag, Stuttgart, 1986).

- Mutations which may be considered are transitions, transversions, insertions and deletions. Depending upon the effect of exchanging the amino acids upon enzyme activity, the mutations are known as missense mutations or nonsense mutations. Insertions or deletions of at least one base pair in a gene give rise to frame shift mutations, as a result of which the incorrect amino acids are inserted or translation terminates prematurely. Deletions of two or more codons typically result in a complete breakdown of enzyme activity. Instructions for producing such mutations belong to the prior art and may be found in known textbooks of genetics and molecular biology, such as for example the textbook by Knippers ("Molekulare Genetik", 6th edition, Georg Thieme Verlag, Stuttgart, Germany, 1995), by Winnacker ("Gene und Klone", VCH Verlagsgesellschaft, Weinheim, Germany, 1990) or by Hagemann ("Allgemeine Genetik", Gustav Fischer Verlag, Stuttgart, 1986).

One example of a plasmid with the assistance of which insertion mutagenesis of the *poxB* gene may be performed is pCR2.1*poxB*int (Figure 1).

Plasmid pCR2.1*poxB*int consists of the plasmid pCR2.1-TOPO described by Mead et al. (Bio/Technology 9:657-663 (1991)), into which an internal fragment of the *poxB* gene, shown in SEQ ID no. 3, has been incorporated. After transformation and homologous recombination into the chromosomal *poxB* gene (insertion), this plasmid results in a total loss of enzyme function. By way of example, the strain DSM5715::pCR2.1*poxB*int, the pyruvate oxidase of which is suppressed, was produced in this manner. Further instructions and explanations relating to insertion mutagenesis may be found, for example, in Schwarzer and Pühler (Bio/Technology 9,84-87 (1991)) or Fitzpatrick et al. (Applied Microbiology and Biotechnology 42, 575-580 (1994)).

It may additionally be advantageous for the production of L-amino acids, in particular L-lysine, in addition to attenuating the *poxB* gene, to amplify, in particular to overexpress, one or more enzymes of the particular biosynthetic pathway, of glycolysis, of anaplerotic metabolism, of the citric acid cycle or of amino acid export.

Thus, for example, for the production of L-lysine

- the *dapA* gene (EP-B 0 197 335), which codes for dihydropicolinate synthase, may simultaneously be overexpressed, or
- the *dapD* gene (Wehrmann et al., Journal of Bacteriology 180, 3159-3165 (1998)), which codes for tetrahydricolinate succinylase, may simultaneously be overexpressed, or

- the *dapE* gene (Wehrmann *et al.*, Journal of Bacteriology 177: 5991-5993 (1995)), which codes for succinyldiaminopimelate desuccinylase, may simultaneously be overexpressed, or
- the *gap* gene (Eikmanns (1992), Journal of Bacteriology 174: 6076-6086), which codes for glyceraldehyde 3-phosphate dehydrogenase, may simultaneously be overexpressed, or
- 5 • the *pyc* gene (Eikmanns (1992), Journal of Bacteriology 174: 6076-6086), which codes for pyruvate carboxylase, may simultaneously be overexpressed, or
- the *mqo* gene (Molenaar *et al.*, European Journal of Biochemistry 254, 395-403 (1998)), which codes for malate:quinone oxidoreductase, may simultaneously be overexpressed, or
- the *lysE* gene (DE-A-195 48 222), which codes for lysine export, may simultaneously be overexpressed.

10

It may furthermore be advantageous for the production of amino acids, in particular L-lysine, in addition to attenuating the *poxB* gene, to suppress unwanted secondary reactions (Nakayama: "Breeding of Amino Acid Producing Micro-organisms", in: Overproduction of Microbial Products, Krumphanzl, Sikyta, Vanek (eds.), Academic Press, London, UK, 1982).

15

The microorganisms containing the polynucleotide of the invention are also provided by the invention and may be cultured continuously or discontinuously using the batch process or the fed batch process or repeated fed batch process for the purpose of producing L-amino acids, in particular L-lysine. A summary of known culture methods is given in the textbook by Chmiel (Bioprozesstechnik 1.

Einführung in die Bioverfahrenstechnik (Gustav Fischer Verlag, Stuttgart, 1991)) or in the textbook by Storhas (Bioreaktoren und periphere Einrichtungen (Vieweg Verlag, Braunschweig/Wiesbaden, 1994)).

- 5 The culture medium to be used must adequately satisfy the requirements of the particular strains. Culture media for various microorganisms are described in "Manual of Methods for General Bacteriology" from the American Society for Bacteriology (Washington D.C., USA, 1981). Carbon sources
- 10 which may be used include sugars and carbohydrates, such as for example glucose, sucrose, lactose, fructose, maltose, molasses, starch and cellulose, oils and fats, such as for example soya oil, sunflower oil, peanut oil and coconut oil, fatty acids, such as for example palmitic acid,
- 15 stearic acid and linoleic acid, alcohols, such as for example glycerol and ethanol, and organic acids, such as for example acetic acid. These substances may be used individually or as a mixture. Nitrogen sources which may be used comprise organic compounds containing nitrogen, such
- 20 as peptones, yeast extract, meat extract, malt extract, corn steep liquor, soya flour and urea or inorganic compounds, such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate. The nitrogen sources may be used individually or
- 25 as a mixture. Phosphorus sources which may be used are phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding salts containing sodium. The culture medium must furthermore contain metal salts, such as for example magnesium sulfate
- 30 or iron sulfate, which are necessary for growth. Finally, essential growth-promoting substances such as amino acids and vitamins may also be used in addition to the above-stated substances. Suitable precursors may furthermore be added to the culture medium. The stated feed substances may
- 35 be added to the culture as a single batch or be fed appropriately during culturing.

Basic compounds, such as sodium hydroxide, potassium hydroxide, ammonia or ammonia water, or acidic compounds, such as phosphoric acid or sulfuric acid, are used appropriately to control the pH of the culture. Antifoaming agents, such as for example fatty acid polyglycol esters, may be used to control foaming. Suitable selectively acting substances, such as for example antibiotics, may be added to the medium in order to maintain plasmid stability. Oxygen or gas mixtures containing oxygen, such as for example air, are introduced into the culture in order to maintain aerobic conditions. The temperature of the culture is normally from 20°C to 45°C and preferably from 25°C to 40°C. The culture is continued until a maximum quantity of the desired product has been formed. This aim is normally achieved within 10 to 160 hours.

- 10 Methods for determining L-amino acids are known from the prior art. Analysis may proceed by anion exchange chromatography with subsequent ninhydrin derivatisation, as described in Spackman *et al.* (Analytical Chemistry, 30, (1958), 1190) or by reversed phase HPLC, as described in Lindroth *et al.* (Analytical Chemistry (1979) 51: 1167-1174).

- 15 The following microorganism has been deposited with Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany) in accordance with the Budapest Treaty on 19 October 1999.

- *Escherichia coli* strain DH5 α /pCR2.1poxBint as DSM 13114.

Examples

The present invention is illustrated in greater detail by the following practical examples.

Example 1

- 5 Production of a genomic cosmid gene library from
Corynebacterium glutamicum ATCC13032

Chromosomal DNA from Corynebacterium glutamicum ATCC13032 was isolated as described in Tauch et al., (1995, Plasmid 33:168-179) and partially cleaved with the restriction
10 enzyme Sau3AI (Amersham Pharmacia, Freiburg, Germany, product description Sau3AI, code no. 27-0913-02). The DNA fragments were dephosphorylated with shrimp alkaline phosphatase (Roche Molecular Biochemicals, Mannheim, Germany, product description SAP, code no. 1758250). The
15 DNA of cosmid vector SuperCos1 (Wahl et al. (1987) Proceedings of the National Academy of Sciences USA 84:2160-2164), purchased from Stratagene (La Jolla, USA, product description SuperCos1 Cosmid Vector Kit, code no. 251301) was cleaved with the restriction enzyme XbaI
20 (Amersham Pharmacia, Freiburg, Germany, product description XbaI, code no. 27-0948-02) and also dephosphorylated with shrimp alkaline phosphatase. The cosmid DNA was then cleaved with the restriction enzyme BamHI (Amersham Pharmacia, Freiburg, Germany, product description BamHI,
25 code no. 27-0868-04). Cosmid DNA treated in this manner was mixed with the treated ATCC13032 DNA and the batch was treated with T4 DNA ligase (Amersham Pharmacia, Freiburg, Germany, product description T4 DNA Ligase, code no. 27-0870-04). The ligation mixture was then packed in phages
30 using Gigapack II XL Packing Extracts (Stratagene, La Jolla, USA, product description Gigapack II XL Packing Extract, code no. 200217). E. coli strain NM554 (Raleigh et al. 1988, Nucleic Acid Res. 16:1563-1575) was infected by suspending the cells in 10 mM MgSO₄ and mixing them with an

aliquot of the phage suspension. The cosmid library was infected and titred as described in Sambrook et al. (1989, Molecular Cloning: A laboratory Manual, Cold Spring Harbor), the cells being plated out on LB agar (Lennox, 1955, Virology, 1:190) + 100µg/ml of ampicillin. After overnight incubation at 37°C, individual recombinant clones were selected.

Example 2

10 Isolation and sequencing of the poxB gene

Cosmid DNA from an individual colony was isolated in accordance with the manufacturer's instructions using the Qiaprep Spin Miniprep Kit (product no. 27106, Qiagen, Hilden, Germany) and partially cleaved with the restriction enzyme Sau3AI (Amersham Pharmacia, Freiburg, Germany, product description Sau3AI, product no. 27-0913-02). The DNA fragments were dephosphorylated with shrimp alkaline phosphatase (Roche Molecular Biochemicals, Mannheim, Germany, product description SAP, product no. 1758250).

20 Once separated by gel electrophoresis, the cosmid fragments of a size of 1500 to 2000 bp were isolated using the QiaExII Gel Extraction Kit (product no. 20021, Qiagen, Hilden, Germany). The DNA of the sequencing vector pZero-1 purchased from Invitrogen (Groningen, Netherlands, product description Zero Background Cloning Kit, product no. K2500-01) was cleaved with the restriction enzyme BamHI (Amersham Pharmacia, Freiburg, Germany, product description BamHI, product no. 27-0868-04). Ligation of the cosmid fragments into the sequencing vector pZero-1 was performed as

30 described by Sambrook et al. (1989, Molecular Cloning: A laboratory Manual, Cold Spring Harbor), the DNA mixture being incubated overnight with T4 ligase (Pharmacia Biotech, Freiburg, Germany). This ligation mixture was then electroporated into the E. coli strain DH5αMCR (Grant,

1990, Proceedings of the National Academy of Sciences U.S.A., 87:4645-4649) (Tauch et al. 1994, FEMS Microbiol Letters, 123:343-7) and plated out onto LB agar (Lennox, 1955, Virology, 1:190) with 50 µg/ml of Zeocin. Plasmids of
5 the recombinant clones were prepared using the Biorobot 9600 (product no. 900200, Qiagen, Hilden, Germany, Germany). Sequencing was performed using the dideoxy chain termination method according to Sanger et al. (1977, Proceedings of the National Academies of Sciences U.S.A.,
10 74:5463-5467) as modified by Zimmermann et al. (1990, Nucleic Acids Research, 18:1067). The "RR dRhodamin Terminator Cycle Sequencing Kit" from PE Applied Biosystems (product no. 403044, Weiterstadt, Germany) was used. Separation by gel electrophoresis and analysis of the
15 sequencing reaction was performed in a "Rotiphorese NF acrylamide/bisacrylamide" gel (29:1) (product no. A124.1, Roth, Karlsruhe, Germany) using the "ABI Prism 377" sequencer from PE Applied Biosystems (Weiterstadt, Germany).
20 The resultant raw sequence data were then processed using the Staden software package (1986, Nucleic Acids Research, 14:217-231), version 97-0. The individual sequences of the pZero 1 derivatives were assembled into a cohesive contig. Computer-aided coding range analysis was performed using
25 XNIP software (Staden, 1986, Nucleic Acids Research, 14:217-231). Further analysis was performed using the "BLAST search programs" (Altschul et al., 1997, Nucleic Acids Research, 25:3389-3402), against the non-redundant database of the "National Center for Biotechnology
30 Information" (NCBI, Bethesda, MD, USA).

The resultant nucleotide sequence is stated in SEQ ID no. 1. Analysis of the nucleotide sequence revealed an open reading frame of 1737 base pairs, which was designated the poxB gene. The poxB gene codes for a polypeptide of 579
35 amino acids.

Example 3

Production of an integration vector for integration mutagenesis of the *poxB* gene

- 5 Chromosomal DNA was isolated from strain ATCC 13032 using the method of Eikmanns et al. (Microbiology 140: 1817 - 1828 (1994)). On the basis of the sequence of the *poxB* gene for *C. glutamicum* known from Example 2, the following oligonucleotides were selected for the polymerase chain
10 reaction:

*poxB*int1:

5' TGC GAG ATG GTG AAT GGT GG 3'

*poxB*int2:

5' GCA TGA GGC AAC GCA TTA GC 3'

- 15 The stated primers were synthesized by the company MWG Biotech (Ebersberg, Germany) and the PCR reaction performed in accordance with the standard PCR method of Innis et al. (PCR protocols. A guide to methods and applications, 1990, Academic Press) using Pwo polymerase from Boehringer. A DNA
20 fragment of approx. 0.9 kb in size, which bears an internal fragment of the *poxB* gene and is shown in SEQ ID no. 3, was isolated with the assistance of the polymerase chain reaction.

- The amplified DNA fragment was ligated into the vector
25 pCR2.1-TOPO (Mead et al. (1991) Bio/Technology 9:657-663) using the TOPO TA Cloning Kit from Invitrogen Corporation (Carlsbad, CA, USA; catalogue no. K4500-01). The *E. coli* strain DH5 α was then electroporated with the ligation batch (Hanahan, in DNA cloning. A practical approach. Vol.I. IRL-
30 Press, Oxford, Washington DC, USA, 1985). Plasmid-bearing cells were selected by plating the transformation batch out onto LB agar (Sambrook et al., Molecular Cloning: A Laboratory Manual. 2nd Ed. Cold Spring Harbor Laboratory

Press, Cold Spring Harbor, N.Y., 1989) which had been supplemented with 25 mg/l of kanamycin. Plasmid DNA was isolated from a transformant using the QIAprep Spin Miniprep Kit from Qiagen and verified by restriction with the restriction enzyme EcoRI and subsequent agarose gel electrophoresis (0.8%). The plasmid was named pCR2.1poxBint.

Example 4

- 10 Integration mutagenesis of the poxB gene into the lysine producer DSM 5715

The vector named pCR2.1poxBint in Example 2 was electroporated into *Corynebacterium glutamicum* DSM 5715 using the electroporation method of Tauch et al. (FEMS Microbiological Letters, 123:343-347 (1994)). Strain DSM 5715 is an AEC-resistant lysine producer. The vector pCR2.1poxBint cannot independently replicate in DSM 5715 and is only retained in the cell if it has been integrated into the chromosome of DSM 5715. Clones with pCR2.1poxBint integrated into the chromosome were selected by plating the electroporation batch out onto LB agar (Sambrook et al., Molecular Cloning: A Laboratory Manual. 2nd Ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.) which had been supplemented with 15 mg/l of kanamycin.

25 Integration was detected by labeling the poxBint fragment with the Dig hybridization kit from Boehringer using the method according to "The DIG System Users Guide for Filter Hybridization" from Boehringer Mannheim GmbH (Mannheim, Germany, 1993). Chromosomal DNA of a potential integrant was isolated using the method according to Eikmanns et al. (Microbiology 140: 1817 - 1828 (1994)) and cut in each case with the restriction enzymes SalI, SacI and HindIII. The resultant fragments were separated by agarose gel electrophoresis and hybridized at 68°C using the Dig

hybridization kit from Boehringer. The plasmid named pCR2.1poxBint in Example 3 had been inserted within the chromosomal poxB gene in the chromosome of DSM 5715. The strain was designated DSM5715::pCR2.1poxBint.

5

Example 5

Production of lysine

The *C. glutamicum* strain DSM5715::pCR2.1poxBint obtained in Example 3 was cultured in a nutrient medium suitable for the production of lysine and the lysine content of the culture supernatant was determined.

To this end, the strain was initially incubated for 24 hours at 33°C on an agar plate with the appropriate antibiotic (brain/heart agar with kanamycin (25 mg/l)). Starting from this agar plate culture, a preculture was inoculated (10 ml of medium in a 100 ml Erlenmeyer flask). The complete medium CgIII was used as the medium for this preculture. Kanamycin (25 mg/l) was added to this medium. The preculture was incubated for 48 hours at 33°C on a shaker at 240 rpm. A main culture was inoculated from this preculture, such that the initial optical density (OD, 660 nm) of the main culture was 0.1 OD. Medium MM was used for the main culture.

25 Medium MM

CSL (Corn Steep Liquor)	5 g/l
MOPS	20 g/l
Glucose (separately autoclaved)	50 g/l

Salts:

(NH ₄) ₂ SO ₄)	25 g/l
KH ₂ PO ₄	0.1 g/l
MgSO ₄ * 7 H ₂ O	1.0 g/l
CaCl ₂ * 2 H ₂ O	10 mg/l
FeSO ₄ * 7 H ₂ O	10 mg/l
MnSO ₄ * H ₂ O	5.0 mg/l
Biotin (sterile-filtered)	0.3 mg/l
Thiamine*HCl (sterile-filtered)	0.2 mg/l
Leucine (sterile-filtered)	0.1 g/l
CaCO ₃	25 g/l

CSL, MOPS and the salt solution are adjusted to pH 7 with ammonia solution and autoclaved. The sterile substrate and vitamin solutions, together with the dry-autoclaved CaCO₃ are then added.

- Culturing is performed in a volume of 10 ml in a 100 ml Erlenmeyer flask with flow spoilers. Kanamycin (25 mg/l) was added. Culturing was performed at 33°C and 80% atmospheric humidity.
- 10 After 48 hours, the OD was determined at a measurement wavelength of 660 nm using a Biomek 1000 (Beckmann Instruments GmbH, Munich). The quantity of lysine formed was determined using an amino acid analyzer from Eppendorf-BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column derivatization with ninhydrin detection.

Table 1 shows the result of the test.

Table 1

Strain	OD(660)	Lysine HCl g/l
DSM 5715	13.1	9.5
DSM5715::pCR2.1poxBint	12.5	12.9

Example 6

Integration mutagenesis of the poxB gene into the valine
5 producer FERM-BP 1763

The vector named pCR2.1poxBint in Example 2 was
electroporated into *Brevibacterium lactofermentum* FERM-BP
1763 using the electroporation method of Tauch et al. (FEMS
Microbiological Letters, 123:343-347 (1994)). Strain FERM-
10 BP 1763 is a mycophenolic acid resistant valine producer
(US-A-5,188,948). The vector pCR2.1poxBint cannot
independently replicate in FERM-BP 1763 and is only
retained in the cell if it has been integrated into the
chromosome of FERM-BP 1763. Clones with pCR2.1poxBint
15 integrated into the chromosome were selected by plating the
electroporation batch out onto LB agar (Sambrook et al.,
Molecular Cloning: A Laboratory Manual. 2nd Ed. Cold Spring
Harbor Laboratory Press, Cold Spring Harbor, N.Y.) which
had been supplemented with 15 mg/l of kanamycin.
20 Integration was detected by labeling the poxBint fragment
with the Dig hybridization kit from Boehringer using the
method according to "The DIG System Users Guide for Filter
Hybridization" from Boehringer Mannheim GmbH (Mannheim,
Germany, 1993). Chromosomal DNA of a potential integrant
25 was isolated using the method according to Eikmanns et al.
(Microbiology 140: 1817 - 1828 (1994)) and cut in each case
with the restriction enzymes Sall, SacI and HindIII. The

resultant fragments were separated by agarose gel electrophoresis and hybridized at 68°C using the Dig hybridization kit from Boehringer. The plasmid named pCR2.1poxBint in Example 3 had been inserted within the
5 chromosomal poxB gene in the chromosome of FERM-BP 1763. The strain was designated FERM-BP 1763::pCR2.1poxBint.

Example 7

Production of valine

- 10 The B. Lactofermentum strain FERM-BP 1763::pCR2.1poxBint obtained in Example 6 was cultured in a nutrient medium suitable for the production of valine and the valine content of the culture supernatant was determined.

- 15 To this end, the strain was initially incubated for 24 hours at 33°C on an agar plate with the appropriate antibiotic (brain/heart agar with kanamycin (25 mg/l)). Starting from this agar plate culture, a preculture was inoculated (10 ml of medium in a 100 ml Erlenmeyer flask). The complete medium CgIII was used as the medium for this
20 preculture. Kanamycin (25 mg/l) was added to this medium. The preculture was incubated for 48 hours at 33°C on a shaker at 240 rpm. A main culture was inoculated from this preculture, such that the initial optical density (OD, 660 nm) of the main culture was 0.1 OD. Medium MM was used for
25 the main culture.

Medium MM

CSL	5 g/l
MOPS	20 g/l

Glucose (separately autoclaved) 50 g/l

Salts:

(NH₄)₂SO₄ 25 g/l

KH₂PO₄ 0.1 g/l

MgSO₄ * 7 H₂O 1.0 g/l

CaCl₂ * 2 H₂O 10 mg/l

FeSO₄ * 7 H₂O 10 mg/l

MnSO₄ * H₂O 5.0 mg/l

Isoleucine (sterile-filtered) 0.1 g/l

Methionine (sterile-filtered) 0.1 g/l

Thiamine*HCl (sterile-filtered) 0.2 mg/l

Leucine (sterile-filtered) 0.1 g/l

CaCO₃ 25 g/l

CSL (corn steep liquor), MOPS (morpholinopropanesulfonic acid) and the salt solution are adjusted to pH 7 with ammonia solution and autoclaved. The sterile substrate and vitamin solutions, together with the dry-autoclaved CaCO₃ are then added.

Culturing is performed in a volume of 10 ml in a 100 ml Erlenmeyer flask with flow spoilers. Kanamycin (25 mg/l) was added. Culturing was performed at 33°C and 80% atmospheric humidity.

After 48 hours, the OD was determined at a measurement wavelength of 660 nm using a Biomek 1000 (Beckmann Instruments GmbH, Munich). The quantity of valine formed

was determined using an amino acid analyzer from Eppendorf-BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column derivatization with ninhydrin detection.

Table 2 shows the result of the test.

5

Table 2

Strain	OD(660)	Valine HCl g/l
FERM-BP 1763	8.6	12.1
FERM-BP 1763::pCR2.1poxB nt	9.5	13.0

10

The following Figures are attached:

Figure 1: Map of the plasmid pCR2.1poxBint.

The abbreviations and names are defined as follows.

ColE1 ori: Replication origin of the plasmid ColE1

lacZ: 5' end of the β -galactosidase gene

f1 ori: Replication origin of the f1 phage

KmR: Kanamycin resistance

Apr: Ampicillin resistance

BamHI: Restriction site of the restriction enzyme BamHI

EcoRI: Restriction site of the restriction enzyme EcoRI

poxBint: Internal fragment of the poxB gene

SEQUENCE LISTING

<110> Degussa-Hüls AG

5 <120> Novel nucleotide sequences coding for the poxB gene

<130> 990159 BT

<140>

10 <141>

<160> 3

<170> PatentIn Ver. 2.1

15

<210> 1

<211> 2160

<212> DNA

<213> Corynebacterium glutamicum

20

<220>

<221> CDS

<222> (327)..(2063)

25

<220>

<221> -35_signal

<222> (227)..(232)

30

<220>

<221> -10_signal

<222> (256)..(261)

<400> 1

35

ttagaggcga ttctgtgagg tttcttttg tggggtcggg gtctaaattt ggccagtttt 60

cgaggcgacc agacaggcgt ggcattatg tttaaataagg cgatcgggtgg gcatctgtgt 120

ttgggttcga cgggctgaaa cttaaacaga ctgccagca acgacggaaa tcccaaaagt 180

40

gggcatccct gtttggtaac gaggacacac cggggcctga aactccctgg caggcggggcg 240

aagcgtggca acaactggaa ttaagagca caattgaagt cgcaccaagt taggcaacac 300

45

aatagccata acgttgagga gttccatg gca cac agc tac gca gaa caa tta 353
Met Ala His Ser Tyr Ala Glu Gln Leu
1 5

50

att gac act ttg gaa gct taa ggt gtg aag cga att tat ggt ttg gtg 401

Ile Asp Thr Leu Glu Ala Gln Gly Val Lys Arg Ile Tyr Gly Leu Val

10 15 20 25

ggg gac agc ctt aat ccg atc gtg gat gct gtc cgc caa tca gat att 449

Gly Asp Ser Leu Asn Pro Ile Val Asp Ala Val Arg Gln Ser Asp Ile

55

gag tgg gtg cac gtt cgc gat gag gaa gcg gcg gcg ttt gca gcc ggt 497

Glu Trp Val His Val Arg Asn Glu Glu Ala Ala Ala Phe Ala Ala Gly

45 50 55

60

gcg gaa tcg ttg atc act ggg gag ctg gca gta tgt gct gct tct tgt 545

Ala Glu Ser Leu Ile Thr Gly Glu Leu Ala Val Cys Ala Ala Ser Cys

60 65 70

	ggt cct gga aac aca cac	gag gac cag ggt ctt tat gat tcg cat cga	593
	Gly Pro Gly Asn Thr His	Glu Gln Gly Leu Tyr Asp Ser His Arg	
	75	85	
5	aat ggt gcg aag gtg ttg	acc ggc gct agc cat att ccg agt gcc cag	641
	Asn Gly Ala Lys Val	Ala Ile Ala Ser His Ile Pro Ser Ala Gln	
	90	100 105	
10	att ggt tcg acg ttc ttc	tag ttc acg cat ccg gag att ttg ttt aag	689
	Ile Gly Ser Thr Phe Phe	Ile Thr His Pro Glu Ile Leu Phe Lys	
	110	115 120	
15	gaa tgc tct ggt tac tgc	acc ggc ggt aat ggt ggt gag cag ggt gaa	737
	Glu Cys Ser Gly Tyr Cys	Ile Thr Val Asn Gly Gly Glu Gln Gly Glu	
	125	130 135	
20	cgc att ttg cat cac gcg	acc ggc tcc acc atg gcg ggt aaa ggt gtg	785
	Arg Ile Leu His His Ala	Ile Thr Ser Thr Met Ala Gly Lys Gly Val	
	140	145 150	
25	tcg gtg gta gtg att cct	atc gct aag gaa gac gca ggt gac	833
	Ser Val Val Val Ile Pro	Gly Asp Ile Ala Lys Glu Asp Ala Gly Asp	
	155	160 165	
30	ggt act tat tcc aat tcc	acc ggc tct tct ggc act cct gtg gtg ttc	881
	Gly Thr Tyr Ser Asn Ser	Thr Thr Ser Ser Gly Thr Pro Val Val Phe	
	170	175 180 185	
35	ccg gat cct act gag gct	acc ggc ctg gtg gag gcg att aac aac gct	929
	Pro Asp Pro Thr Glu Ala	Ile Thr Leu Val Glu Ala Ile Asn Asn Ala	
	190	195 200	
40	aag tct gtc act ttg ttc	acc ggc ggc gtg aag aat gct cgc gcg	977
	Lys Ser Val Thr Leu Phe	Gly Val Lys Asn Ala Arg Ala	
	205	210 215	
45	cag gtg ttg gag ttg gcg	acc ggc att aaa tca ccg atc ggg cat gcg	1025
	Gln Val Leu Glu Leu Ala	Ile Thr Ile Lys Ser Pro Ile Gly His Ala	
	220	225 230	
50	ctg ggt ggt aag cag tac	acc ggc cat gag aat ccg ttt gag gtc ggc	1073
	Leu Gly Gly Lys Glu Tyr	Ile Thr His Glu Asn Pro Phe Glu Val Gly	
	235	240 245	
55	atg tct ggc ctg ctt ggt	acc ggc gcc tgc gtg gat gcg tcc aat gag	1121
	Met Ser Gly Leu Leu Gly	Tyr Thr Ala Cys Val Asp Ala Ser Asn Glu	
	250	255 260 265	
60	gcg gat ctg ctg att cta	acc ggc acc gat ttc cct tat tct gat ttc	1169
	Ala Asp Leu Leu Ile Leu	Thr Thr Thr Asp Phe Pro Tyr Ser Asp Phe	
	270	275 280	
65	ctt cct aaa gac aac ggc	acc ggc gct gat atc aac ggt gcg cac att	1217
	Leu Pro Lys Asp Asn Val	Ile Thr Val Asp Ile Asn Gly Ala His Ile	
	285	290 295	
70	ggt cga cgt acc acc ggt	acc ggc gcc gtg acc ggt gat gtt gct gca	1265
	Gly Arg Arg Thr Thr Val	Gly Thr Pro Val Thr Gly Asp Val Ala Ala	
	300	305 310	
75	aca atc gaa aat acc tcc	acc ggc gtc aag gaa aaa aca gat cgt tcc	1313
	Thr Ile Glu Asn Ile Leu	Thr Thr Val Lys Glu Lys Thr Asp Arg Ser	
	315	320 325	

5	ttc ctt gat cgg atg ttc ac Phe Leu Asp Arg Met Ile Tyr 330	tac gag cgt aag ttg agc tcg gtg His Glu Arg Lys Leu Ser Ser Val 340 345	1361
	gta gag acg tac acc ctt ac Val Glu Thr Tyr Thr Ile Ile 350	gag aag cat gtg cct att cac cct Glu Lys His Val Pro Ile His Pro 355 360	1409
10	gaa tac gtt gcc tcc att ac Glu Tyr Val Ala Ser Ile Ile 365	gag ctg gcg gat aag gat gcg gtg Glu Leu Ala Asp Lys Asp Ala Val 370 375	1457
15	ttt act gtg gat acc ctt ag Phe Thr Val Asp Thr Ile Ile 380	aat gtg tgg cat gcg agg tac atc Asn Val Trp His Ala Arg Tyr Ile 390	1505
20	gag aat ccg gag gga ctt ac Glu Asn Pro Glu Gly Thr Thr 395	ttt gtg ggt tca ttc cgc cac ggc Phe Val Gly Ser Phe Arg His Gly 405	1553
25	acg atg gct aat gcc ttc ct Thr Met Ala Asn Ala Ile Ile 410	ccg att ggt gcg caa agt gtt gat Ala Ile Gly Ala Gln Ser Val Asp 420 425	1601
	cga aac cgc cag ggg att ac Arg Asn Arg Gln Val Thr Thr 430	agt ggc gat ggt ggt ttg ggc atg Lys Gly Asp Gly Gly Leu Gly Met 435 440	1649
30	ctg ctg ggt gag cct att ac Leu Leu Gly Glu Leu Ile Ile 445	agc ctg cac caa ctt ccg ctg aag Lys Leu His Gln Leu Pro Leu Lys 450 455	1697
35	gct gtg gtg ttt aac att ag Ala Val Val Phe Asn Asn Ile 460	ttg ggc atg gtg aag ttg gag atg Leu Gly Met Val Lys Leu Glu Met 470	1745
40	ctc gtg gag gcc cag ctt ac Leu Val Glu Gly Gln Ile Ile 475	gtt act gac cat gag gaa gtg aat Ile Thr Asp His Glu Glu Val Asn 485	1793
45	ttc gcc gag att gag gtt ct Phe Ala Glu Ile Ala Ala Ile 490	agt atc aaa tcg gta cgc atc acc Gly Ile Lys Ser Val Arg Ile Thr 500 505	1841
50	gat ccg aag aaa gtt ctt ag Asp Pro Lys Lys Val Ile Ile 510	cta gct gag gca ttg gca tat cct Leu Ala Glu Ala Leu Ala Tyr Pro 515 520	1889
55	gga cct gta ctg acc ctt ac Gly Pro Val Leu Ile Ile Ile 525	ttg gat cct aat gcg ctg tcg atc Ile Asp Pro Asn Ala Leu Ser Ile 530 535	1937
	cca cca acc acc atg ttc ac Pro Pro Thr Ile Thr Thr Ile 540	ctc atg gga ttc agc aag gcg gcc Ile Met Gly Phe Ser Lys Ala Ala 550	1985
60	acc cga acc gcc att ctt ac Thr Arg Thr Val Ile Ile Ile 555	cta cga gcg atg atc gat ctg gcc Ile Gly Ala Met Ile Asp Leu Ala 565	2033

	cgt tgg gaa ata	tt	tcca tgatgattga tacacctgct	2083
	Arg Ser Val Ile	Asn	Pro	
	570			
5	gtttctcat	aacat	ccatttcca ggatggcagc tcacgccggt	2143
	gccccatga	ctggca		2160
10	<210> 2			
	<211> 57			
	<212> EW			
	<213> CCG Met Val	Ile		
15	<400> 2			
	Met Ala Val Ser Thr	Ile Asp Thr Leu Glu Ala Gln		
	1	10	15	
	Gly Val Asn Arg Val	Gly Asp Ser Leu Asn Pro Ile		
20			30	
	Val Asp Val Val Val	Glu Trp Val His Val Arg Asn		
	5	45		
25	Glu Glu Val Ala	Ala Glu Ser Leu Ile Thr Gly		
	5	60		
	Glu Leu Val Val	Gly Pro Gly Asn Thr His Leu		
30	65	75	80	
	Ile Gln Val Thr Thr	Asn Gly Ala Lys Val Leu Ala		
35		90	95	
	Ile Ala Val His Thr	Ile Gly Ser Thr Phe Phe Gln		
	100	105	110	
	Glu Thr Thr Thr Thr	Glu Cys Ser Gly Tyr Cys Glu		
40	105	125		
	Met Val Thr Gly	Arg Ile Leu His His Ala Ile		
	13	140		
45	Gln Ser Thr Thr Thr	Ser Val Val Val Ile Pro Gly		
	145	155	160	
	Asp Ile Thr Thr Thr	Gly Thr Tyr Ser Asn Ser Thr		
	150	170	175	
50	Ile Ser Thr Thr Thr	Pro Asp Pro Thr Glu Ala Ala		
	155	190		
	Ala Leu Thr Gln Thr	Lys Ser Val Thr Leu Phe Cys		
55	160	205		
	Gly Ala Thr Thr Thr	Gln Val Leu Glu Leu Ala Glu		
	21	220		
60	Lys Ile Thr Thr Thr	Leu Gly Gly Lys Gln Tyr Ile		
	225	235	240	
	Gln His Thr Thr Thr	Met Ser Gly Leu Leu Gly Tyr		

990158 / AL

		250	255
	Gly Ala	Ala Asp Leu Leu Ile Leu Leu	270
5	Gly Thr	Leu Pro Lys Asp Asn Val Ala	285
10	Gln Val	Gly Arg Arg Thr Thr Val Lys	300
	Tyr Pro	Thr Ile Glu Asn Ile Leu Pro	315 320
15	His Val	Phe Leu Asp Arg Met Leu Lys	330 335
	Ala His	Val Glu Thr Tyr Thr His Asn	350
20	Val Glu	Glu Tyr Val Ala Ser Ile Leu	365
25	Asn Glu	Phe Thr Val Asp Thr Gly Met	380
	Cys Asn	Glu Asn Pro Glu Gly Thr Arg	395 400
30	Asp Phe	Thr Met Ala Asn Ala Leu Pro	410 415
	His Ala	Arg Asn Arg Gln Val Ile Ala	430
35	Met Cys	Leu Leu Gly Glu Leu Leu Thr	445
40	Val Lys	Ala Val Val Phe Asn Asn Ser	460
	Ser Leu	Leu Val Glu Gly Gln Pro Glu	475 480
45	Phe Glu	Phe Ala Glu Ile Ala Ala Ala	490 495
	Ala Gly	Asp Pro Lys Lys Val Arg Glu	510
50	Gln Leu	Gly Pro Val Leu Ile Asp Ile	525
55	Val Thr	Pro Pro Thr Ile Thr Trp Glu	540
	Gln Val	Thr Arg Thr Val Phe Gly Gly	555 560
60	Gly Val	Arg Ser Asn Ile Arg Asn Ile	575
	Pro Thr		

5 <210>
 <211>
 <212>
 <213>

10 <400>
 tgcgagc
 accatg
 gcaggc
 gatccg
 15 ttctgc
 aaatca
 gaggtc
 gatctg
 gttgcg
 20 gtgacc
 gatcgt
 gagacg
 attttg
 gtgtgc
 25 cgccac

gcatcagc gattcagtc 60
 gtgatatcgc taaggaagac 120
 gcactcctgt ggtgttcccg 180
 acgctaagtc tgtcactttg 240
 tggagttggc ggagaagatt 300
 tccagcatga gaatccggtt 360
 tggatgcgct caatgaggcg 420
 atttccttcc taaagacaac 480
 gtaccacggt gaagtatccg 540
 ctcattgtgaa ggaaaaaaca 600
 gtaagttgag ctcggtggta 660
 accctgaata cgttgcctct 720
 tggataccgg catgtgcaat 780
 gcgactttgt gggttcattc 840
 875

The claim

that

is:

1. a polynucleotide sequence selected from the group

a)

a) a polynucleotide sequence selected from the

5 for a polynucleotide

and

b) 70% identical to a polynucleotide which codes for a polypeptide which contains an amino acid

sequence

the

acid sequence of SEQ ID no. 2,

com

plementary to the polynucleotides of a) or b), and

at

least 15 successive bases of the polynucleotide

10 sequence

2.

of

claim 1, wherein the polynucleotide is a replicable

DNA.

3.

of

claim 2, wherein the polynucleotide is recombinant.

4.

of

claim 1, wherein the polynucleotide is an RNA.

15 5.

of

claim 2 or claim 3, containing the nucleotide

sequence

1.

6.

of

claim 2 or claim 3, which codes for a

polypeptide

as

shown in SEQ ID no. 2.

7.

of

claim 2 or claim 3, containing

20

seq.

in SEQ ID no. 1, or

ue

matches the sequence (i) within the degeneration

range of

for

hybridises with the complementary sequence to

sequence

the

sequences in (i).

25

the

as hereinbefore described with reference to

8.

of

as hereinbefore described with reference to

any one

of

as claimed in claim 1.

9.

of

containing the polynucleotide as claimed in claim 1,

10.

of

containing the polynucleotide as claimed in claim 1,

30 point d).

the

which contain a deletion or an insertion in the

11.

of

which contain a deletion or an insertion in the

12.

of

which contain a deletion or an insertion in the

poxB gene

13. A process for the production of L-lysine, characterised in that the following steps are performed:

a) culturing the bacteria in a medium containing the desired L-amino acid, in which at

least the concentration of the L-amino acid is at least 0.1 g/l;

5 b) selecting the bacteria which are able to grow in the medium or in the cells of the bacteria;

c) culturing the bacteria in a medium containing the desired L-amino acid, in which at

least the concentration of the L-amino acid is at least 0.1 g/l;

14. A process for the production of L-lysine, characterised in that bacteria are used in which

the concentration of the L-amino acid is at least 0.1 g/l.

10 15. A process for the production of L-lysine, characterised in that bacteria are used in which

the concentration of the L-amino acid is at least partially

suppressed.

16. A process for the production of L-lysine, characterised in that expression of the

polynucleotide as claimed in claim 13, characterised in that the polynucleotide as

15 17. A process for the production of L-lysine, characterised in that the polynucleotide as

claimed in claim 13, characterised in that the polynucleotide as

18. A process for the production of L-lysine, characterised in that the catalytic properties of the

polypeptide as claimed in claim 1 codes are

reduced.

20 19. A process for the production of L-lysine, characterised in that the catalytic properties of the

polypeptide as claimed in claim 1, points a), b) or c) codes, are

reduced.

20. A process for the production of L-lysine, characterised in that bacteria are used in which

the concentration of the L-amino acid is at least 0.1 g/l.

25 21. A process for the production of L-lysine, characterised in that bacteria are used in which

the concentration of the L-amino acid is at least 0.1 g/l.

22. A process for the production of L-lysine, characterised in that bacteria are used in which

the concentration of the L-amino acid is at least 0.1 g/l.

30 23. A process for the production of L-lysine, characterised in that L-lysine is produced by

fermentation of a medium containing the L-lysine, which are

selectively over-expressed which are

• L-lysine decarboxylase,

• (S)-methylcysteine resistance,

• L-lysine carboxylase,

5

herein.

2:

od flaminopimelate desuccinylase,
der hyde 3-phosphate dehydrogenase,
de inone oxidoreducataase
di port.

di no acids, said process being substantially as
co the examples.

co as claimed in any one of claims 13 to 24.

Dat ber, 2000

s engesellschaft

10


ey can/Nominated Person
SP: ERGUSON

Figure

a:

poxBint

3938
3907



3938
3907